# Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

> **NCT01381861** · PHASE2 · COMPLETED · sponsor: **Tracon Pharmaceuticals Inc.** · enrollment: 23 (actual)

## Conditions studied

- Recurrent Ovarian Cancer
- Fallopian Tube Carcinoma
- Primary Peritoneal Carcinoma

## Interventions

- **BIOLOGICAL:** Carotuximab (TRC105)

## Key facts

- **NCT ID:** NCT01381861
- **Lead sponsor:** Tracon Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2012-08
- **Final completion:** 2013-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381861, "Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01381861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*